Role of tachykinin receptors and melatonin in oxytocin secretion from isolated rat hypothalmo-neurohypophysial system

Journal of Physiology and Pharmacology

Volumn 55, Issue 4, 2004, Pages 739-749

  Juszczak, Marlena ^a   Furykiewicz Nykis K ^a   Stempniak, B ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Melatonin; Neurokinin A; NK 1 NK 2 receptors; Oxytocin; Substance P

Indexed keywords

MELATONIN; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR AGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ A; NEUROKININ A [4-10]; NEUROPEPTIDE; OXYTOCIN; SUBSTANCE P; SUBSTANCE P [6-11]; TACHYKININ RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HYPOTHALAMUS; MALE; NONHUMAN; OXYTOCIN RELEASE; RADIOIMMUNOASSAY; RAT; SUPRAOPTIC NUCLEUS; THALAMUS MIDLINE NUCLEUS;

ANIMALS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MELATONIN; OXYTOCIN; PITUITARY GLAND, POSTERIOR; RATS; RATS, WISTAR; RECEPTORS, TACHYKININ;

EID: 11144233674     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Crowley WR, Armstrong WE. Neurochemical regulation of oxytocin secretion in lactation. Endocr Rev 1992; 13: 33-65.
2. Juszczak M, Stempniak B. The effect of melatonin on suckling-induced oxytocin and prolactin release in the rat. Brain Res Bull 1997; 44: 253-258.
3. Ciosek J. Vasopressin and oxytocin release as influenced by thyrotropin-releasing hormone in euhydrated and dehydrated rats. J Physiol Pharmacol 2002; 53: 423-437.
4. Ciosek J, Cisowska A, Dabrowski R. Galanin affects vasopressin and oxytocin release from the hypothalamo-neurohypophysial system in haemorrhaged rats. J Physiol Pharmacol 2003; 54: 233-246.
5. Juszczak M, Steger RW, Fadden C, Bartke A. Oxytocin and prolactin release after hypertonic saline administration in melatonin-treated male Syrian hamsters. J Physiol Pharmacol 1996; 47: 289-301.
6. Juszczak M. Melatonin affects the oxytocin and prolactin responses to stress in male rats. J Physiol Pharmacol 1998; 49: 151-163.
7. Chowdrey HS, Lightman SL. Role of central amino acids and peptide-mediated pathways in neurohypophysial hormone release. Ann NY Acad Sci 1993; 689: 183-193.
8. Bojanowska E, Juszczak M, Guzek JW, Da̧browski R. Luteinizing hormone-releasing hormone and oxytocin response to hyperosmotic stimulation: in vitro study. Brain Res Bull 2000; 52: 303-307.
9. Bojanowska E, Stempniak B. TGLP-1 and release of vasopressin and oxytocin from the isolated rat hypothalamo-neurohypophysial system: effects of a TGLP-1 receptor agonist and antagonist. J Physiol Pharmacol 2001; 52: 781-793.
10. Jessop DS, Chowdrey HS, Lightman SL. Substance P and substance K in the median eminence and paraventricular nucleus of the rat hypothalamus. Neuropeptides 1990; 17: 135-140.
11. Bittencourt JC, Benoit R, Sawchenko PE. Distribution and origins of substance P-immunoreactive projections to the paraventricular and supraoptic nuclei: partial overlap with ascending catecholaminergic projections. J Chem Neuroanat 1991; 4: 63-78.
12. Larsen PJ, Jessop DS, Chowdrey HS, Mikkelsen JD, Lightman SL. Osmotic regulation of substance P and neurokinin A peptide content and substance P binding sites in distinct hypothalamic nuclei of the rat. Peptides 1992; 13: 705-712.
13. Debeljuk L, Bartke A. Immunoreactive substance P and neurokinin A in the hypothalamus and anterior pituitary gland of Siberian and Syrian hamsters and of rats. J Reprod Fertil 1994; 101: 427-434.
14. Duval P, Lenoir V, Moussaoui S, Garret C, Kerdelhue B. Substance P and neurokinin A variations throughout the rat oestrous cycle; comparison with ovariectomized and male rats: I. Plasma, hypothalamus, anterior and posterior pituitary. J Neurosci Res 1996; 45: 598-609.
15. Mikkelsen JD, Larsen PJ, Moller M, Vilhardt H, Sarmark T. Substance P in the median eminence and pituitary of the rat: demonstration of immunoreactive fibres and specific binding sites. Neuroendocrinology 1989; 50: 100-108.
16. Mikkelsen JD, Schmidt P, Sheikh SP, Larsen PJ. Non-vasopressinergic, non-oxytocinergic neuropeptides in the rat hypothalamo-neurohypophyseal tract: experimental immunohistochemical studies. Prog Brain Res 1992; 91: 367-371.
17. Larsen PJ, Jessop DS, Lightman SL, Chowdrey HS. Preprotachykinin A gene expression in distinct hypothalamic and brain stem regions of the rat is affected by a chronic osmotic stimulus: a combined immunohistochemical and in situ hybridization histochemistry study. Brain Res Bull 1993; 30: 535-545.
18. Liu HL, Cao R, Jin L, Chen LW. Immunocytochemical localization of substance P receptor in hypothalamic oxytocin-containing neurons of C57 mice. Brain Res 2002; 948: 175-179.
19. Clarke G, Kirby PJC, Thomson AM. Effect on vasopressinergic and oxytocinergic neurones of intraventricular substance P. J Physiol (London) 1980; 307: 59P.
20. Chiodera P, Coiro V. Effects of intravenous infusion of substance P on arginine vasopressin and oxytocin secretion in normal men. Brain Research 1992; 569: 173-176.
21. De Laurentiis A, Pisera D, Duvilanski B, Rettori V, Lasaga M, Seilicovich A. Neurokinin A inhibits oxytocin and GABA release from the posterior pituitary by stimulating nitric oxide synthase. Brain Res Bull 2000; 53: 325-330.
22. Harlan RE, Garcia MM, Krause JE. Cellular localization of substance P- and neurokinin A-encoding preprotachykinin mRNA in the female rat brain. J Comp Neurol 1989; 287: 179-212.
23. Nevin K, Zhuo H, Helke CJ. Neurokinin A coexists with substance P and serotonin in ventral medullary spinally projecting neurons of the rat. Peptides 1994; 15: 1003-1011.
24. Torrens Y, Beaujouan J-C, Dietl M, Saffroy M, Petitet F, Glowinski J. Tachykinin receptors: binding and cellular activity assays. Methods Neurosci 1991; 5: 243-267.
25. Guartara L, Maggi CA. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 1988; 32: 1-49.
26. Dam TV, Escher E, Quirion R. Evidence for the existence of three classes of neurokinin receptors in brain. Differential ontogeny of neurokinin-1, neurokinin-2 and neurokinin-3 binding sites in rat cerebral cortex. Brain Res 1988; 453: 372-376.
27. Hagan RM, Beresford IJM, Stables J, et al. Characterization, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists. Reg Pept 1993; 46: 9-19.
28. Maggi CA, Giuliani S, Ballati L, et al. In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376. J Pharmacol Exp Ther 1991; 257: 1172-1178.
29. Maggi CA, Patacchini R, Rovero P, Santicioli P. Tachykinin receptors and noncholinergic bronchoconstriction in the guinea-pig isolated bronchi. Am Rev Respir Dis 1991; 144: 363-367.
30. Maggi CA, Patacchini R, Santicioli P, Giuliani S. Tachykinin antagonists and capsaicin-induced contraction of the rat isolated urinary bladder: evidence for tachykinin-mediated cotransmission. Br J Pharmacol 1991; 103: 1535-1541.
31. Maggi CA, Patacchini R, Meini S et al. Comparison of tachykinin NK1 and NK2 receptors in the circular muscle of the guinea-pig ileum and proximal colon. Br J Pharmacol 1994; 112: 150-160.
32. Wiesenfeld-Hallin Z, Luo L, Xu XJ, Maggi CA. Differential effects of selective tachykinin NK2 receptor antagonists in rat spinal cord. Eur J Pharmacol 1994; 251: 99-102.
33. Juszczak M, Stempniak B, Guzek JW. Melatonin, pinealectomy and release of neurohypophysial hormones: in vitro studies. J Pineal Res 1992; 12: 1-6.
34. Juszczak M, Debeljuk L, Bartke A, Stempniak B. Melatonin inhibits oxytocin and vasopressin release from the neurointermediate lobe of the hamster pituitary. Neuroreport 1995; 6: 2453-2456.
35. Yasin SA, Costa A, Besser GM, Hucks D, Grossman A, Forsling ML. Melatonin and its analogs inhibit the basal and stimulated release of hypothalamic vasopressin and oxytocin in vitro. Endocrinology 1993; 132: 1329-1336.
36. Yasin SA, Grossman A, Forsling ML. Diurnal variation in the effect of melatonin on neurohypophysial hormone release from the rat hypothalamus. Brain Res Bull 1996; 39: 1-5.
37. Juszczak M. Neurokinin A and the neurohypophysial response to melatonin: in vitro studies. J Physiol Pharmacol 2002; 53: 823-834.
38. Juszczak M, Stempniak B. Melatonin inhibits the substance P-induced secretion of vasopressin and oxytocin from the rat hypothalamo-neurohypophysial system: in vitro studies. Brain Res Bull 2003; 59: 393-397.
39. Kapoor JR, Sladek CD. Substance P and NPY differentially potentiate ATP and adrenergic stimulated vasopressin and oxytocin release. Am J Physiol 2001; 280: R69-78.
40. Sakurada T, Manome Y, Tan-No K, et al. A selective and extremely potent antagonist of the neurokinin-1 receptor. Brain Res 1992; 593: 319-322.
41. Maeno H, Kiyama H, Tohyama M. Distribution of the substance P receptor (NK-1 receptor) in the central nervous system. Mol Brain Res 1993; 18: 43-58.
42. Liu C, Weaver DR, Jin L, Chen LW. Molecular dissection of two distinct actions of melatonin on the suprachiasmaticus circadian clock. Neuron 1997; 19: 91-102.
43. Hermes MLHJ, Coderre EM, Buijs RM, Renaud LP. GABA and glutamate mediate rapid neurotransmission from suprachiasmatic nucleus to hypothalamic paraventricular nucleus in rat. J Physiol 1996; 496: 749-757.
44. Cui LN, Saeb-Parsy K, Dyball REJ. Neurons in the supraoptic nucleus of the rat are regulated by a projection from the suprachiasmatic nucleus. J Physiol 1997; 502: 149-159.
45. Mikkelsen JD, Larsen PJ. Substance P in the suprachiasmatic nucleus of the rat: an immunohistochemical and in situ hybridization study. Histochemistry 1993; 100: 3-16.
46. Reiter RJ, Oh C-S, Fujimori O. Melatonin: its intracellular and genomic actions. Trends Endocrinol Metab 1996; 7: 22-27.
47. Wiesenberg I, Missbach M, Kahlen J-P, Schrader M, Carlberg C. Transcriptional activation of the nuclear receptor RZRα by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res 1995; 23: 327-333.
48. Alexiuk NAM, Vriend JP. Melatonin reduces dopamine content in the neurointermediate lobe of male Syrian hamsters. Brain Res Bull 1993; 32: 433-436.
49. Alexiuk NAM, Uddin M, Vriend JP. Melatonin increases the in situ activity of tyrosine hydroxylase in the mediobasal hypothalamus of male Syrian hamsters. Life Sci 1996; 59: 687-694.
50. Yasin SA, Forsling ML. Mechanisms of melatonin inhibition of neurohypophysial hormone release from the rat hypothalamus in vitro. Brain Res Bull 1998; 45: 53-59.
51. Vanecek J, Watanabe K. Mechanisms of melatonin action in the pituitary and SCN. Adv Exp Med Biol 1999; 460: 191-198.